权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical Core - Pharmacogenomics of Statin Therapy (POST)

临床核心 - 他汀类药物治疗的药物基因组学 (POST)

基本信息

批准号：
9326329
负责人：
Carlos Iribarren
金额：
$ 38.56万
依托单位：
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9326329
关键词：
Adopted Adult Adverse effects Aging Biomedical Research California Caring Cell model Clinical Clinical Research Collection Computerized Medical Record Coronary DNA Data Data Analytics Data Set Diabetes Mellitus Disease Electronic Health Record Environment Event Exposure to Feces Future Genes Genotype Group Practice Guidelines Health Human In Vitro Individual Informatics Lipids Medical Metabolic Molecular Myopathy Participant Patients Pharmacogenomics Pharmacologic Substance Pharmacy facility Plasma Population Population Heterogeneity Prospective cohort study Recording of previous events Records Recruitment Activity Research Resources Role Sampling Simvastatin Site Standardization Stroke Study Subject System Variant Whole Blood adverse outcome base biobank c new clinical practice cohort database query design epidemiology study ethnic diversity exome follow-up genetic analysis genetic epidemiology genetic information genome wide association study genome-wide health care delivery healthy aging lymphoblastoid cell line member phenotypic data programs racial diversity response socioeconomics transcriptomics

项目摘要

CLINICAL CORE: PROJECT SUMMARY The Clinical Core at the Division of Research, Kaiser Permanente of Northern California (KPNC) is a key component of the overall POST Center. It serves a vital role by providing all the human participants for Project 1, and all the genotypic data, phenotypic data, and DNA samples to Project 3. The aims of the POST Clinical Core are: 1) To obtain whole blood and plasma from KPNC statin users with a) a major adverse coronary event (MACE, N=124) while on treatment, b) statin-induced myopathy (N=124), c) new onset diabetes (N=124), and d) three sets of 124 matched controls (N=372) for the studies in Project 1 (“Molecular Determinants of Statin Efficacy and Adverse Effects using Cellular Models”, Drs. Medina and Krauss); 2) With Project 3 (“Genome-wide Association Study of Statin Response and its Consequences”, Dr. Risch), create a dataset of medical and pharmacy information relevant to statin effects on lipids, MACE, stroke, statin-induced myopathy and new onset diabetes from the electronic medical records of patients in the GERA cohort; and 3) Provide DNA samples from selected statin users within the GERA cohort (n=2,517) and within the extended Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) biorepository (n=843) to Project 3 for follow-up genetic analysis of candidate loci identified throughout the Center's research program.

临床核心：项目总结